Alterations of arterial physiology in osteopontin-null mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 6, 2003, Pages 1021-1028

  Myers, Daniel L ^a   Harmon, Kelley J ^a   Lindner, Volkhard ^a,b   Liaw, Lucy ^a,b  

^a Maine Medical Center Research Institute   (United States)

^b UNIVERSITY OF MAINE   (United States)

Author keywords

Cardiovasculature; Carotid artery; Flow cessation; Osteopontin; Remodeling

Indexed keywords

COLLAGEN; OSTEOPONTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL COMPLIANCE; CARDIOVASCULAR SYSTEM; CAROTID ARTERY LIGATION; CELL INVASION; CONTROLLED STUDY; HEART RATE; INFLAMMATION; LEUKOCYTE ADHERENCE; LYMPHOCYTE; MOUSE; NONHUMAN; NULL ALLELE; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; WILD TYPE;

ANIMALS; ARTERIES; BLOOD PRESSURE; CAROTID STENOSIS; CHEMOTAXIS, LEUKOCYTE; COLLAGEN; HEART RATE; HEMODYNAMIC PROCESSES; LEUKOCYTE COUNT; LIGATION; MALE; MICE; MICE, KNOCKOUT; OSTEOPONTIN; PHENOTYPE; SIALOGLYCOPROTEINS; TUNICA INTIMA; VASCULAR RESISTANCE; VASCULITIS;

EID: 0037783268     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000073312.34450.16     Document Type: Article

References (74)

1. Kawasaki T, Dewerchin M, Lijnen HR, Vreys I, Vermylen J, Hoylaerts MF. Mouse carotid artery ligation induces platelet-leukocyte-dependent luminal fibrin, required for neointima development. Circ Res. 2001;88:159-166.
2. Kumar A, Hoover JL, Simmons CA, Lindner V, Shebuski RJ. Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice. Circulation. 1997;96:4333-4342.
3. Rogers C, Edelman ER, Simon DI. A mAb to the β2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci U S A. 1998;95:10134-10139.
4. Simon DI, Dhen Z, Seifert P, Edelman ER, Ballantyne CM, Rogers C. Decreased neointimal formation in Mac-1(-/-) mice reveals a role for inflammation in vascular repair after angioplasty. J Clin Invest. 2000;105:293-300.
5. Sata M, Walsh K. Fas ligand-deficient mice display enhanced leukocyte infiltration and intima hyperplasia in flow-restricted vessels. J Mol Cell Cardiol. 2000;32:1395-1400.
6. Nugent HM, Rogers C, Edelman ER. Endothelial implants inhibit intimal hyperplasia after porcine angioplasty. Circ Res. 1999;84:384-391.
7. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest. 1998;101:731-736.
8. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
9. Kumar A, Lindner V. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol. 1997;17:2238-2244.
10. Murakami H, Yayama K, Miao RQ, Wang C, Chao L, Chao J. Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension. 1999;34:164-170.
11. Emanueli C, Salis MB, Chao J, Chao L, Agata J, Lin KF, Munao A, Straino S, Minasi A, Capogrossi MC, Madeddu P. Adenovirus-mediated human tissue kallikrein gene delivery inhibits neointima formation induced by interruption of blood flow in mice. Arterioscler Thromb Vasc Biol. 2000;20:1459-1466.
12. Weiler H, Lindner V, Kerlin B, Isermann BH, Hendrickson SB, Cooley BC, Meh DA, Mosesson MW, Shworak NW, Post MJ, Conway EM, Ullman LH, von Andrian UH, Weitz JI. Characterization of a mouse model for thrombomodulin deficiency. Arterioscler Thromb Vasc Biol. 2001;21:1531-1537.
13. Bendeck MP, Regenass S, Tom WD, Giachelli CM, Schwartz SM, Hart C, Reidy MA. Differential expression of α1 type VIII collagen in injured platelet-derived growth factor-BB-stimulated rat carotid arteries. Circ Res. 1996;79:524-531.
14. Rectenwald JE, Moldawer LL, Huber TS, Seeger JM, Ozaki CK. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation. 2000;102:1697-1702.
15. Smith JD, Bryant SR, Couper LL, Vary CP, Gotwals PJ, Koteliansky VE, Lindner V. Soluble transforming growth factor-β type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res. 1999;84:1212-1222.
16. Yamashita T, Kawashima S, Ozaki M, Rikitake Y, Hirase T, Inoue N, Hirata K, Yokoyama M. A calcium channel blocker, benidipine, inhibits intimal thickening in the carotid artery of mice by increasing nitric oxide production. J Hypertens. 2001;19:451-458.
17. Laurent S, Tropeano AI, Lillo-Lelouet A, Jondeau G, Laloux B, Boutouyrie P. Local pulse pressure is a major determinant of large artery remodelling. Clin Exp Pharmacol Physiol. 2001;28:1011-1014.
18. Hochleimer BW, Hochleimer EO, Obrist P, Eberl T, Amberger A, Xu Q, Margreiter R, Wick G. Fluid shear stress induces heat shock protein 60 expression in endothelial cells in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2000;20:617-623.
19. Song RH, Kocharyan HK, Fortunato JE, Glagov S, Bassiouny HS. Increased flow and shear stress enhance in vivo transforming growth factor-β1 after experimental arterial injury. Arterioscler Thromb Vasc Biol. 2000;20:923-930.
20. Liaw L, Lombardi DM, Almeida MM, Schwartz SM, deBlois D, Giachelli CM. Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Arterioscler Thromb Vasc Biol. 1997;17:188-193.
21. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993;92:1686-1696.
22. Tai JT, Brooks EE, Liang S, Somogyi R, Rosete JD, Lawn RM, Shiffman D. Determination of temporal expression patterns for multiple genes in the rat carotid artery injury model. Arterioscler Thromb Vasc Biol. 2000;20:2184-2191.
23. Weber GF, Cantor H. The immunology of Eta-1/osteopontin. Cytokines Growth Factor Rev. 1996;7:241-248.
24. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107:1055-1061.
25. McKee MD, Nanci A. Secretion of osteopontin by macrophages and its accumulation at tissue surfaces during wound healing in mineralized tissues: a potential requirement for macrophage adhesion and phagocytosis. Anat Rec. 1996;245:394-409.
26. Giachelli CM, Liaw L, Murry CE, Schwartz SM, Almeida M. Osteopontin expression in cardiovascular diseases. Ann N Y Acad Sci. 1995;760:109-126.
27. Lesauskaite V, Tanganelli P, Sassi C, Neri E, Diciolla F, Ivanoviene L, Epistolato MC, Lalinga AV, Alessandrini C, Spina D. Smooth muscle cells of the media in the dilatative pathology of ascending thoracic aorta: morphology, immunoreactivity for osteopontin, matrix metalloproteinases, and their inhibitors. Hum Pathol. 2001;32:1003-1011.
28. Liaw L, Lindner V, Schwartz SM, Chambers AF, Giachelli CM. Osteopontin and β3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ Res. 1995;77:665-672.
29. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res. 1994;74:214-224.
30. Wada T, McKee MD, Steitz S, Giachelli CM. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res. 1999;84:166-178.
31. Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem. 2000;275:20197-20203.
32. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000;287:860-864.
33. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol. 1998;152:353-358.
34. Chiba S, Okamoto H, Kon S, Kimura C, Murakami M, Inobe M, Matsui Y, Sugawara T, Shimizu T, Uede T, Kitabatake A. Development of atherosclerosis in osteopontin transgenic mice. Heart Vessels. 2002;16:111-117.
35. Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res. 1998;58:5206-5215.
36. Asou Y, Rittling SR, Yoshitake H, Tsuji K, Shinomiya K, Nifuji A, Denhardt DT, Noda M. Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone. Endocrinology. 2001;142:1325-1332.
37. Trueblood NA, Xie Z, Communal C, Sam F, Ngoy S, Liaw L, Jenkins AW, Wang J, Sawyer DB, Bing OH, Apstein CS, Colucci WS, Singh K. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res. 2001;88:1080-1087.
38. Ihara H, Denhardt DT, Furuya K, Yamashita T, Muguruma Y, Tsuji K, Hruska KA, Higashio K, Enomoto S, Nifuji A, Rittling SR, Noda M. Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J Biol Chem. 2001;276:13065-13071.
39. Ishijima M, Rittling SR, Yamashita T, Tsuji K, Kurosawa H, Nifuji A, Denhardt DT, Noda M. Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med. 2001;193:399-404.
40. Yoshitake H, Rittling SR, Denhardt DT, Noda M. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption [published erratum appears in Proc Natl Acad Sci U S A. 1999;96:10944]. Proc Natl Acad Sci U S A. 1999;96:8156-8160.
41. Liaw L. Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL. Altered wound healing in mice lacking a functional osteopontin gene (sppl). J Clin Invest. 1998;101:1468-1478.
42. Mazzali M, Hughes J, Dantas M, Liaw L, Steitz S, Alpers CE, Pichler RH, Lan HY, Giachelli CM, Shankland SJ, Couser WG, Johnson RJ. Effects of cyclosporine in osteopontin null mice. Kidney Int. 2002;62:78-85.
43. Ophascharoensuk V, Giachelli CM, Gordon K, Hughes J, Pichler R, Brown P, Liaw L, Schmidt R, Shankland SJ, Alpers CE, Couser WG, Johnson RJ. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int. 1999;56:571-580.
44. Noiri E, Dickman K, Miller F, Romanov G, Romanov VI, Shaw R, Chambers AF, Rittling SR, Denhardt DT, Goligorsky MS. Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene. Kidney Int. 1999;56:74-82.
45. Weiss JM, Renkl AC, Maier CS, Kimmig M, Liaw L, Ahrens T, Kon S, Maeda M, Hotta H, Uede T, Simon JC. Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. J Exp Med. 2001;194:1219-1229.
46. Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S, Nifuji A, Uede T, Denhardt DT, Noda M. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci U S A. 2002;99:4556-4561.
47. Speer MY, McKee MD, Guldberg RE, Liaw L, Yang HY, Tung E, Karsenty G, Giachelli CM. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med. 2002;196:1047-1055.
48. Isoda K, Nishikawa K, Kamezawa Y, Yoshida M, Kusuhara M, Moroi M, Tada N, Ohsuzu F. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res. 2002;91:77-82.
49. Intengan HD, Deng LY, Li JS, Schiffrin EL. Mechanics and composition of human subcutaneous resistance arteries in essential hypertension. Hypertension. 1999;33:569-574.
50. Schiffers PM, Henrion D, Boulanger CM, Colucci-Guyon E, Langa-Vuves F, van Essen H, Fazzi GE, Levy BI, De Mey JG. Altered flow-induced arterial remodeling in vimentin-deficient mice. Arterioscler Thromb Vasc Biol. 2000;20:611-616.
51. Li DY, Faury G, Taylor DG, Davis EC, Boyle WA, Mecham RP, Stenzel P, Boak B, Keating MT. Novel arterial pathology in mice and humans hemizygous for elastin. J Clin Invest. 1998;102:1783-1787.
52. Kon S, Yokosaki Y, Maeda M, Segawa T, Horikoshi Y, Tsukagoshi H, Rashid MM, Morimoto J, Inobe M, Shijubo N, Chambers AF, Uede T. Mapping of functional epitopes of osteopontin by monoclonal antibodies raised against defined internal sequences. J Cell Biochem. 2002;84:420-432.
53. Hart CY, Burnett JC Jr, Redfield MM. Effects of avertin versus xylazineketamine anesthesia on cardiac function in normal mice. Am J Physiol Heart Circ Physiol. 2001;281:H1938-H1945.
54. Dart AM, Kingwell BA. Pulse pressure: a review of mechanisms and clinical relevance. J Am Coll Cardiol. 2001;37:975-984.
55. Ferguson JJ 3rd, Randall OS. Hemodynamic correlates of arterial compliance. Cathet Cardiovasc Diagn. 1986;12:376-380.
56. Stergiopulos N, Westerhof N. Determinants of pulse pressure. Hypertension. 1998;32:556-559.
57. Thybo NK, Mulvany MJ, Jastrup B, Nielsen H, Aalkjaer C. Some pharmacological and elastic characteristics of isolated subcutaneous small arteries from patients with essential hypertension. J Hypertens. 1996;14:993-998.
58. Hajdu MA, Baumbach GL. Mechanics of large and small cerebral arteries in chronic hypertension. Am J Physiol. 1994;266:H1027-H1033.
59. Campbell DI. Cardiac output determination using compliance. Anaesthesia. 2002;57:1137.
60. Butler WT. Structural and functional domains of osteopontin. Ann N Y Acad Sci. 1995;760:6-11.
61. Kaartinen MT, Pirhonen A, Linnala-Kankkunen A, Maenpaa PH. Cross-linking of osteopontin by tissue transglutaminase increases its collagen binding properties. J Biol Chem. 1999;274:1729-1735.
62. Mukherjee BB, Nemir M, Beninati S, Cordella-Miele E, Singh K, Chackalaparampil I, Shanmugam V, DeVouge MW, Mukherjee AB. Interaction of osteopontin with fibronectin and other extracellular matrix molecules. Ann N Y Acad Sci. 1995;60:201-212.
63. Ritter NM, Farach-Carson MC, Butler WT. Evidence for the formation of a complex between osteopontin and osteocalcin. J Bone Miner Res. 1992;7:877-885.
64. Dobrin PB, Canfield TR. Elastase, collagenase, and the biaxial elastic properties of dog carotid artery. Am J Physiol. 1984;247:H124-H131.
65. Hoffman AS, Grande LA, Park JB. Sequential enzymolysis of human aorta and resultant stress-strain behavior. Biomater Med Devices Artif Organs. 1977;5:121-145.
66. Silver FH, Horvath I, Foran DJ. Viscoelasticity of the vessel wall: the role of collagen and elastic fibers. Crit Rev Biomed Eng. 2001;29:279-301.
67. Vouyouka AG, Pfeiffer BJ, Liem TK, Taylor TA, Mudaliar J, Phillips CL. The role of type 1 collagen in aortic wall strength with a homotrimeric. J Vasc Surg. 2001;33:1263-1270.
68. Kawashima S, Yamashita T, Ozaki M, Ohashi Y, Azumi H, Inoue N, Hirata K, Hayashi Y, Itoh H, Yokoyama M. Endothelial NO synthase overexpression inhibits lesion formation in mouse model of vascular remodeling. Arterioscler Thromb Vasc Biol. 2001;21:201-207.
69. Yogo K, Shimokawa H, Funakoshi H, Kandabashi T, Miyata K, Okamoto S, Egashira K, Huang P, Akaike T, Takeshita A. Different vasculoprotective roles of NO synthase isoforms in vascular lesion formation in mice. Arterioscler Thromb Vasc Biol. 2000;20:E96-E100.
70. Singh R, Pan S, Mueske CS, Witt T, Kleppe LS, Peterson TE, Slobodova A, Chang JY, Caplice NM, Simari RD. Role for tissue factor pathway in murine model of vascular remodeling. Circ Res. 2001;89:71-76.
71. Bryant SR, Bjercke RJ, Erichsen DA, Rege A, Lindner V. Vascular remodeling in response to altered blood flow is mediated by fibroblast growth factor-2. Circ Res. 1999;84:323-328.
72. Tolbert T, Thompson JA, Bouchard P, Oparil S. Estrogen-induced vasoprotection is independent of inducible nitric oxide synthase expression: evidence from the mouse carotid artery ligation model. Circulation. 2001;104:2740-2745.
73. Abramson JL, Weintraub WS, Vaccarino V. Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension. 2002;39:197-202.
74. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001;38:399-403.